Articles by Leah Sherwood
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
The authors reported clinically meaningful responses of luspatercept treatment from patients enrolled in the COMMANDS trial.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care.
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.
Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.